Changchun BCHT Biotechnology Past Earnings Performance
Past criteria checks 5/6
Changchun BCHT Biotechnology has been growing earnings at an average annual rate of 10.2%, while the Biotechs industry saw earnings growing at 5.9% annually. Revenues have been growing at an average rate of 9.2% per year. Changchun BCHT Biotechnology's return on equity is 9.9%, and it has net margins of 25.8%.
Key information
10.2%
Earnings growth rate
6.6%
EPS growth rate
| Biotechs Industry Growth | 11.3% |
| Revenue growth rate | 9.2% |
| Return on equity | 9.9% |
| Net Margin | 25.8% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Changchun BCHT Biotechnology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1,608 | 414 | 745 | 178 |
| 30 Jun 24 | 1,883 | 527 | 867 | 197 |
| 31 Mar 24 | 1,916 | 543 | 889 | 212 |
| 31 Dec 23 | 1,825 | 501 | 861 | 198 |
| 30 Sep 23 | 1,449 | 301 | 733 | 171 |
| 30 Jun 23 | 1,190 | 219 | 640 | 144 |
| 31 Mar 23 | 1,113 | 183 | 611 | 139 |
| 31 Dec 22 | 1,071 | 182 | 586 | 134 |
| 30 Sep 22 | 1,123 | 222 | 563 | 137 |
| 30 Jun 22 | 1,061 | 179 | 538 | 159 |
| 31 Mar 22 | 1,093 | 205 | 522 | 167 |
| 31 Dec 21 | 1,202 | 244 | 567 | 157 |
| 30 Sep 21 | 1,304 | 309 | 640 | 141 |
| 30 Jun 21 | 1,424 | 377 | 681 | 123 |
| 31 Mar 21 | 1,489 | 424 | 718 | 92 |
| 31 Dec 20 | 1,441 | 418 | 689 | 93 |
| 31 Dec 19 | 976 | 221 | 518 | 65 |
| 31 Dec 18 | 1,019 | 128 | 676 | 62 |
Quality Earnings: 688276 has high quality earnings.
Growing Profit Margin: 688276's current net profit margins (25.8%) are higher than last year (20.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 688276's earnings have grown by 10.2% per year over the past 5 years.
Accelerating Growth: 688276's earnings growth over the past year (37.7%) exceeds its 5-year average (10.2% per year).
Earnings vs Industry: 688276 earnings growth over the past year (37.7%) exceeded the Biotechs industry 0.08%.
Return on Equity
High ROE: 688276's Return on Equity (9.9%) is considered low.